Research
Hormonal
IGF1 levels are positively associated with prostate cancer risk, while IGFBP3 levels are inversely associated, suggesting their potential as prognostic markers.
For men with prostate cancer, IGF1 and IGFBP3 levels may help predict outcomes. High IGF1 and low IGFBP3 are associated with worse prognosis.
ModerateSupportsMEDIUM confidence
However, another recent clinical study has indicated that IGF1 is positively associated and IGFBP3 is inversely associated with all-cause mortality in men with advanced prostate cancer (Rowlands et al. 2012), indicating that levels of IGF1 and IGFBP3 may have potential as prognostic markers in predicting risk of death in men with advanced prostate cancer.
Why this rating
Based on specific clinical studies, but the paper notes controversial data and the need for larger cohorts.
Source
Insulin resistance and cancer: the role of insulin and IGFs
Séfirin Djiogue et al. · Endocrine Related Cancer · 2012
DOI 10.1530/erc-12-0324
narrative_reviewCited 261×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intentional weight loss reduces cancer incidence by lowering pro-inflammatory factors and estrogen levels, rather than by significantly altering IGF1 levels.Good
- Hyperinsulinemia in type 2 diabetes increases cancer risk by upregulating IR-A and IGF1R receptors on cancer cells, promoting growth through PI3K/Akt and MAPK pathways.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →